Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Thermo Fisher Scientific    TMO

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : Provides Update to Second Quarter Outlook and Will Hold its Q2 Earnings Conference Call on Wednesday July 22 2020

share with twitter share with LinkedIn share with facebook
07/07/2020 | 10:27am EDT

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that, based on currently available information, it estimates that both reported and organic revenue1 growth will be approximately 10% for the second quarter ended June 27, 2020.

The better-than-expected organic revenue growth was primarily driven by strong global sales of PCR-based tests and other products and services supporting the COVID-19 response, which contributed more than $1.4 billion of revenue in the second quarter and reflects the scale of the company's role in helping customers battle the pandemic.

Thermo Fisher will release its financial results for the second quarter on Wednesday, July 22, 2020, before the market opens, and will hold a conference call to discuss those results and provide a business update on the same day at 8:30 a.m. ET.

To listen, call (833) 714-0931 within the U.S. or (778) 560-2662 outside the U.S. The conference ID is 1239877. You may also listen to the call live on the 'Investors' section of our website, www.thermofisher.com. The earnings press release and related information can be found in that section of our website under 'Financial Results.' A replay of the call will be available under 'Webcasts and Presentations' through Friday, July 31, 2020.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $25 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 75,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

Forward-Looking Statements

The following constitutes a 'Safe Harbor' statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties, including statements about expected revenue growth and long-term impacts of the COVID-19 pandemic. Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: the duration and severity of the COVID-19 pandemic; the need to develop new products and adapt to significant technological change; implementation of strategies for improving growth; general economic conditions and related uncertainties; dependence on customers' capital spending policies and government funding policies; the effect of economic and political conditions and exchange rate fluctuations on international operations; use and protection of intellectual property; the effect of changes in governmental regulations and the effect of laws and regulations governing government contracts, as well as the possibility that expected benefits related to recent or pending acquisitions, including our pending acquisition of QIAGEN N.V., may not materialize as expected. Additional important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in our Quarterly Report on Form 10-Q for the quarter ended March 28, 2020, which is on file with the SEC and available in the 'Investors' section of our website under the heading 'SEC Filings.' While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.

Organic revenue is reported revenue excluding the impact of acquisitions and divestitures and foreign currency translation.

Contact:

Karen Kirkwood:

Tel: 781-622-1306

Email: karen.kirkwood@thermofisher.com

(C) 2020 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
Latest news on THERMO FISHER SCIENTIFIC
08/04THERMO FISHER SCIENTIFIC INC. : Other Events, Financial Statements and Exhibits ..
AQ
08/04THERMO FISHER SCIENTIFIC : Confirms Offer to Acquire QIAGEN Shares Expires on Au..
PR
08/04THERMO FISHER SCIENTIFIC : OIE Approves Registration of VetMAX African Swine Fev..
AQ
08/03THERMO FISHER SCIENTIFIC : China Approves Thermo Fisher Scientific's African Swi..
PU
07/31THERMO FISHER SCIENTIFIC : Management's Discussion and Analysis of Financial Con..
AQ
07/31THERMO FISHER SCIENTIFIC : Scientific nProber IV Delivers Faster Easier Failure ..
AQ
07/29THERMO FISHER SCIENTIFIC : and Lyell Immunopharma Form Cell Therapy Manufacturin..
AQ
07/29THERMO FISHER SCIENTIFIC : - Chemical Analyzer Now Enhances Identification of Lo..
AQ
07/28THERMO FISHER SCIENTIFIC : Expands GlobalAccess Sequencing Program
AQ
07/24THERMO FISHER SCIENTIFIC : - FDA Clears First Blood Test for Identifying a Novel..
AQ
More news
Financials (USD)
Sales 2020 28 041 M - -
Net income 2020 4 456 M - -
Net Debt 2020 12 658 M - -
P/E ratio 2020 37,1x
Yield 2020 0,21%
Capitalization 164 B 164 B -
EV / Sales 2020 6,32x
EV / Sales 2021 5,94x
Nbr of Employees 75 000
Free-Float 90,6%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Average target price 442,72 $
Last Close Price 415,72 $
Spread / Highest target 20,3%
Spread / Average Target 6,50%
Spread / Lowest Target -34,8%
EPS Revisions
Managers
NameTitle
Marc N. Casper Chairman, President & Chief Executive Officer
Mark P. Stevenson Chief Operating Officer & Executive Vice President
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Scott M. Sperling Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
THERMO FISHER SCIENTIFIC27.97%164 454
DANAHER CORPORATION34.27%146 727
INTUITIVE SURGICAL, INC.15.62%80 214
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.87.75%60 074
ILLUMINA, INC.18.67%56 178
BOSTON SCIENTIFIC CORPORATION-17.85%54 146